R Kreis, BD Ross, NA Farrow, Z Ackerman (1992), Metabolic disorders of the brain in chronic hepatic disorders detected with H-1 MR spectroscopy. Radiology: January, 182: 19-27.
A Palatnik, K Frolov, M Fux (2001), Double-blind, controlled, crossover trial of inositol versus fluv. for the treatment of panic disorder. Journal of Clinical Psychopharmacology:June, Vol. 21(3): 335-339.
E Papaleo et al.(2007), Myo-inositol in patients with polycystic ovary syndr: A novel method for ovulation induction. Gynecological Endocrinology: Vol. 23(12): 700-703.
AD Genazzani et al.(2008), Myo-inositol administration positively affects hyperinsulinemia and hormonal parameters in overweight patients with polycystic ovary syndr. Gynecological Endocrinology, Vol. 24(3): 139–144.
E Papaleo et al.(2009), Contribution of myo-inositol to reproduction. European Journal of Obstetrics & Gynecology and Reproductive Biology 147:120–123.
Giordano et al.(2011), Effects of myo-inositol supplementation in postmenopausal women with metabolic syndr: a perspective, randomized, placebo-controlled study. Menopause, January, Vol. 18 (1): 102-104.
J Levine (1997), Controlled trials of inositol in psychiatry. European Neuropsychopharmacology, Vol. 7 (2): 147-155.
A Palatnik, K Frolov, M Fux (2001), Double-blind, controlled, crossover trial of inositol versus fluv. for the treatment of panic disorder. Journal of Clinical Psychopharmacology:June, Vol. 21 (3): 335-339.
L Colodny, D Pharm, RL Hoffman (1998), Inositol – Clinical Applications for Exogenous Use. Alternative Medicine Review, Vol. 3, (6).
E Papaleo (2009), Myo-inositol may improve oocyte quality in intracytoplasmic sperm injection cycles. A prospective, controlled, randomized trial. Fertility and Sterility, Vol. 91 (5) 1750-1754.
A D Genazzani et al.(2008), Myo-inositol administration positively affects hyperinsulinemia and hormonal parameters in overweight patients with polycystic ovary syndr. Gynecological Endocrinology, Vol. 24(3): 139–144.
S Gerli et al. (2007), Randomized, double blind placebo-controlled trial: effects of Myo-inositol on ovarian function and metabolic factors in women with PCOS. Eur. Rev. Med. and Pharmacol. Sci., (11): 347-354.
A Santamaria et al.(2012),One-year effects of myo-inositol supplementation in postmenopausal women with metabolic syndrome. Climacteric, Vol. 15 (5) : Pages 490-495.
A A Lopez-Gonzalez et al. (2013), Protective effect of myo-inositol hexaphosphate (phytate) on bone mass loss in postmenopausal women. European Journal of Nutrition, Vol. 52 (2) 717-726.
SY Atezaz Saeed et al.(2007),Herbal and Dietary Supplements for Treatment of Anxiety Disorders. Am Fam Physician, Vol.76 :549-56.
E Papaleo et al.(2009),Contribution of myo-inositol to reproduction. European Journal of Obstetrics & Gynecology and Reproductive Biology 147:120–123.
D Heber et al.(2007)PDR for Herbal medicines. IV edition Thomson
S Bratman, D Kroll (2000) Natural Health Bible. 2nd edition. Prima Health
R Kreis, BD Ross, NA Farrow, Z Ackerman (1992), Metabolic disorders of the brain in chronic hepatic problems detected with H-1 MR spectroscopy. Radiology: January, 182: 19-27.
A Palatnik, K Frolov, M Fux (2001), Double-blind, controlled, crossover trial of inositol versus fluv. for the treatment of panic disorder. Journal of Clinical Psychopharmacology:June, Vol. 21(3): 335-339.
E Papaleo et al.(2007), Myo-inositol in patients with polycystic ovary syndr: A novel method for ovulation induction. Gynecological Endocrinology: Vol. 23(12): 700-703.
AD Genazzani et al.(2008), Myo-inositol administration positively affects hyperinsulinemia and hormonal parameters in overweight patients with polycystic ovary syndr. Gynecological Endocrinology, Vol. 24(3): 139–144.
E Papaleo et al.(2009), Contribution of myo-inositol to reproduction. European Journal of Obstetrics & Gynecology and Reproductive Biology 147:120–123.
Giordano et al.(2011), Effects of myo-inositol supplementation in postmenopausal women with metabolic syndrome: a perspective, randomized, placebo-controlled study. Menopause, January, Vol. 18 (1): 102-104.
Panni A. et al (2020) Inositol and Non-Alcoholic Fatty Liver Disease: A Systematic Review on Deficiencies and Supplementation. Nutrients 2020, 12, 3379; doi:10.3390/nu12113379
Cabrera-Cruz H.,Oróstica X., Plaza-Parrochia F.,Torres-Pinto I.,Romero C.,and Vega M. (2020) The insulin-sensitizing mechanism of myo-inositol is associated with AMPK activation and GLUT-4 expression in human endometrial cells exposed to a PCOS environment. Am J Physiol Endocrinol Metab 318: E237–E248.
